140 related articles for article (PubMed ID: 16312139)
1. Febuxostat (Teijin/Ipsen/TAP).
Tomlinson B
Curr Opin Investig Drugs; 2005 Nov; 6(11):1168-78. PubMed ID: 16312139
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Schumacher HR
Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat versus allopurinol for gout.
Lustberg ME
N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
[No Abstract] [Full Text] [Related]
11. [Febuxostat].
Wittköpper K; Emons J; El-Armouche A
Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
[No Abstract] [Full Text] [Related]
12. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat (Uloric) for chronic treatment of gout.
Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
Yu KH
Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat versus allopurinol for gout.
Gelber AC
N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
[No Abstract] [Full Text] [Related]
17. Febuxostat for gout.
Drug Ther Bull; 2010 Jul; 48(7):78-82. PubMed ID: 20631196
[TBL] [Abstract][Full Text] [Related]
18. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Hoshide S; Takahashi Y; Ishikawa T; Kubo J; Tsuchimoto M; Komoriya K; Ohno I; Hosoya T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1117-8. PubMed ID: 15571212
[TBL] [Abstract][Full Text] [Related]
19. Gout therapeutics: new drugs for an old disease.
Burns CM; Wortmann RL
Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
[TBL] [Abstract][Full Text] [Related]
20. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).
Ojha R; Singh J; Ojha A; Singh H; Sharma S; Nepali K
Expert Opin Ther Pat; 2017 Mar; 27(3):311-345. PubMed ID: 27841045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
